New developments in the management of prostate cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5 SUPPL., 2013, Pages 653-657

  Kantoff, Philip W ^a   Mohler, James L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONFERENCE PAPER; HUMAN; HYPOCALCEMIA; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; THREAT;

EID: 84882739580     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0194     Document Type: Conference Paper

References (11)

1. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;26:364:1995-2005.
2. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148.
3. Rathkopf DE, Smith MR, De Bono JS, et al. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Presented at the 2013 Genitourinary Cancers Symposium. Abstract 5.
4. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
6. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011;377:813-822.
7. Vogelzang NJ, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride: impact on skeletal-related events in patients with castration-resistant prostate cancer and bone metastases from phase 3 randomized trial (ALYMPCA) [abstract]. J Clin Oncol 2013;31(Suppl 6): Abstract 11.
8. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-1154.
9. Buethe DD, Pow-Sang J. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Netw 2012;10:1101-1110.
10. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-3978.
11. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999;54:884-890.